ODI Pharma AB (publ) reported earnings results for the third quarter and nine months ended March 31, 2024. For the third quarter, the company reported sales was SEK 13.86 million compared to SEK 0.010801 million a year ago. Revenue was SEK 13.95 million compared to SEK 0.024544 million a year ago. Net income was SEK 1.3 million compared to net loss of SEK 0.944121 million a year ago. Basic earnings per share from continuing operations was SEK 0.09 compared to basic loss per share from continuing operations of SEK 0.06 a year ago.
For the nine months, sales was SEK 14.78 million compared to SEK 0.112083 million a year ago. Revenue was SEK 17.92 million compared to SEK 0.15093 million a year ago. Net income was SEK 0.863831 million compared to net loss of SEK 4.37 million a year ago. Basic earnings per share from continuing operations was SEK 0.06 compared to basic loss per share from continuing operations of SEK 0.29 a year ago.